Maralixibat + Placebo

Phase 3Withdrawn

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Progressive Familial Intrahepatic Cholestasis (PFIC)

Conditions

Progressive Familial Intrahepatic Cholestasis (PFIC)

Trial Timeline

Oct 25, 2018 → Jun 15, 2020

NCT ID

NCT03353454

About Maralixibat + Placebo

Maralixibat + Placebo is a phase 3 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis (PFIC). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03353454. Target conditions include Progressive Familial Intrahepatic Cholestasis (PFIC).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03353454	Phase 3	Withdrawn	Oct 25, 2018	Jun 15, 2020	Progressive Familial Intrahepatic Cholestasis (PFIC)

Competing Products

20 competing products in Progressive Familial Intrahepatic Cholestasis (PFIC)

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
Enzalutamide + Placebo	Astellas Pharma	Phase 3	77
Enzalutamide	Astellas Pharma	Phase 2	52
dirucotide + Placebo	Eli Lilly	Phase 2/3	65
dirucotide	Eli Lilly	Phase 2/3	65
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	77
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	52
Placebo + ABBV-8E12	AbbVie	Phase 2	52
ABBV-8E12	AbbVie	Phase 1	33
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	52
antisense oligonucleotide + placebo	Novartis	Phase 1	33
Trametinib 2 mg	Novartis	Pre-clinical	23
Everolimus	Novartis	Phase 2	52
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	23
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	77
FTY720 + Placebo	Novartis	Phase 3	77
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	85
Mayzent	Novartis	Pre-clinical	23
BAF312 + Placebo	Novartis	Phase 3	77
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)	Novartis	Phase 1/2	41

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved